Neuron-Specific Expression of the Rat Gonadotropin-Releasing Hormone Gene Is Conferred by Interactions of a Defined Promoter Element with the Enhancer in GT17 Cells
Shelley B. Nelson,
Mark A. Lawson,
Carolyn G. Kelley and
Pamela L. Mellon
Departments of Reproductive Medicine and Neuroscience
University of California, San Diego La Jolla, California
92093-0674
 |
ABSTRACT
|
---|
Neuroendocrine control of the reproductive
cascade is mediated by GnRH, which in mammals is produced by a subset
of neurons scattered throughout the hypothalamus and forebrain.
Utilizing a cultured cell model of GnRH neurons (GT17 cells), two
regulatory regions in the rat GnRH 5' flanking DNA were identified as
essential for cell-type specificity: a 300-bp enhancer and a 173-bp
conserved proximal promoter. Using transient transfections to compare
expression in GT17 cells to a non-GnRH-expressing cell type (NIH
3T3), we show that the GnRH enhancer and the proximal promoter each
play roles in conferring this specificity. Deletion of footprint 2
(FP2; -26 to -76) from the promoter when coupled to the GnRH enhancer
diminishes reporter activity in GT17 cells more strongly than in NIH
3T3 cells. Furthermore, deletion of FP2 from the promoter when coupled
to the heterologous Rous sarcoma virus 5'-long terminal repeat promoter
abolishes the difference in reporter activity between GT17 and NIH
3T3 cells, suggesting that FP2 of the GnRH promoter is necessary for
cell-specific expression. In addition, FP2 alone is sufficient to
confer cell-specific expression and can interact with the GnRH enhancer
to augment reporter gene expression specifically in GT17 cells.
Finally, a 31-bp sequence from within FP2 (-63 to -33)
synergistically activates transcription when coupled with the GnRH
enhancer in GT17 cells but not in NIH 3T3 cells. Thus, this 31-bp
region contains elements necessary for interaction between the GnRH
enhancer and promoter. We show that two of five protein complexes that
bind to the -63 to -33 region are GT17 cell specific, and both of
them appear to be homeodomain proteins. The identification of a
cell-specific element in the GnRH proximal promoter significantly
advances our understanding of the transcriptional basis for
neuron-specific GnRH gene expression.
 |
INTRODUCTION
|
---|
GnRH, an essential reproductive hormone expressed in a restricted
subset of neurons scattered throughout the hypothalamus of mammals, is
a decapeptide secreted in a pulsatile manner from axonal terminals at
the median eminence (1, 2). GnRH neurons have a unique embryological
origin, migrating from the olfactory placode where they arise at
embryonic day 11 in the mouse (3). Currently, the only known unique
identifier of GnRH neurons is GnRH itself. However, determinants of
cell identity must be involved in the development and maintenance of
GnRH gene expression. These genes could either encode specific
transcriptional activators or a unique combination of more generally
expressed transcription factors expressed only in GnRH neurons.
An excellent model system for examination of GnRH gene transcription is
the GT17 cell line. The GT17 cell line was immortalized by
targeting the oncogene, SV40 T antigen, to GnRH neurons using the
5'-flanking region of the rat GnRH gene in transgenic mice. The
culturing of a hypothalamic tumor derived from such mice facilitated
the clonal isolation of the GT11, GT13, and GT17 cell lines (4).
These cell lines have been invaluable in studying GnRH gene expression,
allowing a detailed analysis of the rat GnRH gene regulatory region. A
300-bp enhancer (-1863 to -1571) was identified by deletion analysis
of a 3-kb 5'-regulatory region of the rat GnRH gene (5). Additionally,
a conserved 173-bp promoter was identified by cross-species similarity
(6). Fusion of the GnRH enhancer to the GnRH promoter in a reporter
gene plasmid recapitulates the activity seen with the 3-kb 5'-flanking
region in transient transfection assays (5) and in transgenic mice
(M. A. Lawson, S. B. Nelson, and P. L. Mellon,
unpublished).
Many transcription factors have been found to interact with the
rat GnRH regulatory regions including Oct-1, GATA-4, SCIP/Tst-1, and
Otx2 (Refs. 7, 8, 9, 10). All of these proteins were identified utilizing
the GT17 GnRH neuronal model system, and colocalization with GnRH has
been confirmed in vivo by immunohistochemistry and/or
in situ hybridization. Oct-1, a POU-homeodomain
transcription factor, binds to two regions within the GnRH enhancer and
two regions within the GnRH promoter (7, 11). GATA-4 binds to one site
in the GnRH enhancer, and its expression colocalizes with GnRH neurons
during embryonic development (8, 9, 12). In vitro
synthesized SCIP binds to regions within the GnRH promoter and
colocalizes with GnRH expression during mouse embryonic development
(10). Otx2, a homeoprotein required for anterior head development
(13, 14, 15) related to the Orthodenticle gene in Drosophila,
binds to a single site in the promoter and colocalizes with GnRH in the
embryo during migration and in the adult hypothalamus (10A ). Although a
few of the proteins that bind to the rat GnRH enhancer and promoter
have now been identified, none of these proteins is restricted uniquely
to the GnRH neurons, supporting the hypothesis that a unique
combination of proteins control GnRH-specific expression.
Interactions between the rat GnRH enhancer and promoter are
important for maintaining a high level of reporter gene transcription
specifically in GT17 cells. The enhancer activates transcription of
the heterologous Herpesvirus thymidine kinase promoter (TK) only 4 fold
in GT17 cells, yet when placed upstream of the GnRH promoter, the
enhancer activates transcription 55-fold (5). Therefore, interactions
must exist between the enhancer and promoter to cause this specific
increase in transcriptional activity in GT17 cells. We have devised a
transient transfection paradigm to compare reporter gene expression
between different cell lines. This approach has allowed us to determine
that a 62-bp region of the GnRH promoter (footprint 2; FP2) is
necessary and sufficient to confer neuronal specificity of GnRH gene
expression in vitro. Additionally, a 31-bp element from
within FP2 acts synergistically with the enhancer and binds two GT17
cell-specific protein complexes, both of which may be homeodomain
proteins.
 |
RESULTS
|
---|
Individual Roles for the Enhancer and Promoter in GT17
Cell-Specific Expression of the Rat GnRH Gene
The rat GnRH regulatory region contains a 300-bp neuron-specific
enhancer (-1863 to -1571) and a conserved 173-bp promoter. To test
the participation of these two regions in conferring neuron-specific
transcription, each element was placed into a heterologous context
(Fig. 1
). To accomplish this, chimeric
regulatory regions were constructed using the GnRH enhancer and
promoter and the enhancer and promoter elements of the Rous sarcoma
virus (RSV) 5'-long terminal repeat (LTR). Specifically, the
heterologous RSV enhancer was fused to the GnRH promoter
(RSVe/rGnRHp-luc), and the GnRH enhancer was fused to the RSV promoter
(rGnRHe/RSVp-luc). These regulatory regions were engineered upstream of
the luciferase reporter gene in a reporter plasmid vector. As controls,
reporter genes containing the RSV enhancer on the RSV promoter
(RSVe/RSVp-luc) or the combination of the GnRH enhancer and promoter
(rGnRHe/rGnRHp-luc) were also prepared. These plasmids were transfected
into four different cell lines, NIH 3T3 (mouse fibroblasts), GT17
(mouse GnRH expressing neurons), JEG-3 (human placental), and CV1
(monkey kidney fibroblasts). To control for differences in transfection
efficiency and relative expression level in various cell types, the RSV
enhancer and the RSV promoter fused to the Escherichia coli
ß-galactosidase gene (RSVe/RSVp-gal) was used as an internal control
in all transfections. The ratio of RSVe/RSVp-luc values to
RSVe/RSVp-gal values was set to 1 for each cell type. The relative
expression levels of the various reporter genes in the cell types
indicated in Fig. 1
are depicted on a log scale since the differences
are dramatic. There is a significantly higher level of reporter gene
expression in GT17 cells than in the other three cell types with the
rGnRHe/rGnRHp-luc, rGnRHe/RSVp-luc, and RSVe/rGnRHp-luc regulatory
regions. These data show that the GnRH enhancer and the GnRH promoter
each play roles in determining GT17 cell-specific expression and that
the combination of the GnRH enhancer and promoter together yields a
synergistic degree of specificity.

View larger version (36K):
[in this window]
[in a new window]
|
Figure 1. The Rat GnRH Enhancer and Promoter Have Individual
Roles in Cell Type-Specific Expression
Transient transfections were conducted in JEG-3, CV1, NIH 3T3, and
GT17 cells (identified by hatched, black, white, and
gray bars, respectively). Diagrams at
left depict luciferase reporter plasmids: the RSV enhancer
fused to the RSV promoter (RSVe/RSVp-luc), the GnRH enhancer (-1863 to
-1571) fused to the GnRH promoter (-173 to +112) (rGnRHe/rGnRHp-luc),
the GnRH enhancer fused to the RSV promoter (rGnRHe/RSVp-luc), and the
RSV enhancer fused to the GnRH promoter (RSVe/rGnRHp-luc). The mean
value for the RSVe/RSVp-luc divided by RSVe/RSVp-gal (internal control)
is set to 1 for each cell type as shown. Error bars represent
SEM of at least three experiments conducted in duplicate.
Asterisks designate statistical differences from GT17
values of P = 0.001. Note that the x-axis is shown
as a log scale to accommodate the large differences in expression.
|
|
FP2 Is Necessary for Cell-Specific Expression
Previously, seven protein-binding regions within the rat GnRH
promoter were identified by DNAse I protection assays (DNA
footprinting) with GT17 nuclear extract (6, 16). Footprint 1 (FP1)
contains the TATA box and transcriptional start site. Deletion of
footprint 2 (FP2, -26 to -76) results in a 20-fold loss of reporter
gene activity in GT17 cells. Footprint 3 (FP3, -79 to -85) does not
bind proteins in electrophoretic mobility shift assays (EMSA), but a
complex does form on this region with nuclear proteins from GT17
cells treated with human chorionic gonadotropin (17). Footprint 4 (FP4,
-89 to -110) binds at least five protein complexes in EMSA, one of
which is Oct-1 (11). Footprint 5 (FP5, -112 to -127) binds one
protein complex in EMSA. Deletion of three footprints, 3, 4, and 5,
results in a 50% reduction in reporter gene activity (6). Deletion of
footprint 6 (FP6, -129 to -158) and footprint 7 (FP7, -161 to -173)
also results in a 50% decrease in reporter gene activity (6).
Additionally, it has been shown that Otx-2 binds to FP6 and a 4-bp
mutation in the binding site reduces activity to 20% of wild type
(10A ). Thus, all of these regions contribute to activation of
transcription of the GnRH gene.
To identify the cell-specific element(s), 5' and internal deletions
were created within the GnRH promoter and transfected into GT17
cells, and the results were compared with those from parallel
transfections into NIH 3T3 cells. Subsections of the promoter
containing various footprinted regions were placed downstream of the
GnRH enhancer (Fig. 2A
), as previously
described by Eraly et al. (6), or the heterologous RSV
enhancer (Fig. 2B
). Here, we have used vectors containing the
luciferase reporter gene instead of the chloramphenicol transferase
reporter gene. When the 5' and internally deleted promoter regions are
placed downstream of the GnRH enhancer, reporter expression in GT17
cells was consistently higher than in NIH 3T3 cells (Fig. 2A
). This
result demonstrates that the GnRH enhancer can confer specificity in a
heterologous context (5). The relative difference in reporter gene
expression between the two cell types can be calculated by dividing the
GT17 values by the NIH 3T3 values (Fig. 2A
at right,
relative activity). It is apparent from these comparisons that a large
decrease in cell type specificity occurs when FP2 is individually
deleted and when FP2 through FP7 are deleted (note the log scale). The
role for FP2 in cell type specificity is further substantiated by
transient transfections with the deletions placed downstream of the RSV
enhancer (Fig. 2B
). Here again, there is a higher level of reporter
gene expression in GT17 cells compared with the NIH 3T3 cells with
the full-length 173-bp promoter although the degree of difference is
diminished due to the lack of the GnRH enhancer. The individual
deletion of FP2 results in a loss of cell type specificity since both
the GT17 cells and the NIH 3T3 cells express the reporter gene to the
same degree. Additionally, when FP2 was reinserted, cell specificity
reappears. It remains unclear why deletion of FP2 through FP7 does not
completely abolish the cell-specific expression, but this result may
indicate that there is some specificity inherent to the TATA box
machinery.

View larger version (46K):
[in this window]
[in a new window]
|
Figure 2. Deletion of Footprint 2 Decreases the Ratio of
GT17 to NIH 3T3 Activity When Coupled to the GnRH Enhancer and
Eliminates the Cell Type-Specific Difference When Coupled to the RSV
Enhancer
Transient transfections were conducted in NIH 3T3 and GT17 cells
(identified by white and gray bars,
respectively). The mean value for RSVe/RSVp-luc divided by
RSVe/RSVp-gal is set to 1 for each cell type (bars shown in A but not
in B). The activity ratios are the values in GT17 cells divided by
the values in the NIH 3T3 cells. A, The GnRH enhancer fused to the
full-length GnRH promoter or deletions of the GnRH promoter are shown
at left. Values are depicted on a log scale. B, The RSV
enhancer fused to the full-length GnRH promoter or deletions of the
GnRH promoter are shown at left.
Asterisks identify significant differences between the
GT17 and NIH 3T3 values by paired t test,
P = 0.001. Error bars represents
SEM of at least three experiments conducted in duplicate.
|
|
FP2 (-82 to -21) or -63/-33 Can Interact with the GnRH Enhancer
to Augment Expression
To test for interactions of FP2 with the GnRH enhancer, FP2 (-82
to -21) was inserted between the GnRH enhancer and the heterologous
RSV promoter (rGnRHe/FP2/RSVp-luc). The insertion of FP2 into this
context results in a large increase in reporter gene expression in
GT17 cells in comparison to NIH 3T3 cells (Fig. 3A
). To determine whether a smaller
region of FP2 can confer cell type specificity, transcriptional
analysis of a 4-fold multimerized -63 to -33 region (4x-63/-33)
was conducted. The reporter plasmids contained the GnRH enhancer fused
to 4x-63/-33 and the RSV promoter (rGnRHe/4X63/RSVp-luc). When
transfected into GT17 cells, rGnRHe/4X63/RSVp-luc increased reporter
gene expression compared with the rGnrHe/RSVp-luc (Fig. 3A
). This
increase was not as great as that seen with FP2, but it does suggest
that 4x -63/-33 synergizes with the GnRH enhancer. Thus, we can
conclude that both FP2 and 4x-63/-33 can act synergistically with
the GnRH enhancer to confer cell type specificity.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 3. Footprint 2 Is Sufficient to Confer Cell Type
Specificity
A, Footprint 2 synergizes with the GnRH enhancer to augment reporter
gene expression exclusively in GT17 cells. B, FP2 in a heterologous
context is sufficient to increase cell type specificity but the
multimerized -63/-33 element is not. Transient transfections were
conducted in NIH 3T3 and GT17 cells (identified by
white and gray bars, respectively). The
mean value for the RSVe/RSVp-luc divided by RSVe/RSVp-gal is set to 1
for each cell type (shown in B, but not in A). The activity ratios are
the values in GT17 cells divided by values in NIH 3T3 cells, shown at
right. Diagrams at left depict luciferase
reporter plasmids: A, the GnRH enhancer fused to the GnRH promoter, the
GnRH enhancer fused to the RSV promoter, FP2 inserted between the GnRH
enhancer and the RSV promoter, and 4x-63/-33 inserted between the
GnRH enhancer and the RSV promoter; B, the RSV enhancer fused to the
RSV promoter, FP2 inserted between the RSV enhancer and promoter, and
4x-63/-33 inserted between the RSV enhancer and promoter.
Asterisks represent significant difference between
values in GT17 and NIH 3T3 cells by paired t test,
P < 0.01. Error bars represent
SEM of at least three experiments conducted in duplicate.
|
|
FP2, but Not -63/-33, Is Sufficient to Confer Neuron-Specific
Expression
To determine whether the FP2 region can enhance neuronal
specificity in a completely heterologous context, FP2 was inserted
between the RSV enhancer and the RSV promoter (RSVe/FP2/RSVp-luc). Here
we see a significant decrease in reporter gene expression in both cell
types (Fig. 3B
) possibly due to the additional 62 bp inserted between
the RSV enhancer and promoter. Regardless of this overall decrease in
expression, there is a higher level of reporter gene expression in
GT17 cells compared with NIH 3T3 cells. Additionally, transfections
into
T31 (a mouse pituitary gonadotrope cell line immortalized in
the same manner as GT17 cells) and IMR-32 (a human neuroblastoma cell
line), showed lower relative activity than expression in NIH 3T3 cells
(data not shown), indicating that NIH 3T3 cells provide the best
comparison with GT17 cells. Internal block mutations within FP2 in
the context of the RSV enhancer and GnRH promoter did not result in a
change in the relative difference between reporter expression in GT17
vs. NIH 3T3 cells (data not shown). Thus, specific sequences
required for this GT17 cell-specific expression could not be further
localized. To determine whether the smaller region of FP2 is able to
confer cell type specificity, transcriptional analysis of the 4-fold
multimerized -63 to -33 region was conducted. The reporter plasmids
contained the RSV enhancer fused to 4x -63/-33 and the RSV promoter
(RSVe/4X63/RSVp-luc). Reporter gene expression levels were higher in
NIH 3T3 cells than in GT17 cells, demonstrating that the 4x-63/-33
is not able to act independently when placed in a heterologous context.
Thus, we have identified FP2 as the smallest region (62 bp) of the GnRH
promoter that is sufficient to autonomously confer cell-specific
expression of the GnRH gene.
Complexes Specific to GT17 Nuclear Extract Bind the -63/-33
Element
Interactions between the GnRH enhancer and GnRH promoter are
likely what confer the cell-specific expression of the GnRH gene based
on our evidence (
Figs. 13

) and evidence obtained in transgenic mice
(M. A. Lawson and P. L. Mellon, unpublished observations).
Having demonstrated that both FP2 and the -63 to -33 promoter
elements interact with the enhancer to specify reporter gene expression
to GT17 cells, we next wanted to determine what proteins may bind to
this region to confer cell specificity. We chose to analyze the -63 to
-33 region because it contains fewer potential protein binding sites,
while still maintaining the capability of interacting with the GnRH
enhancer to confer cell specificity. Previously, we have identified
five GT17 nuclear protein complexes binding to -63/-33, one of
which is Oct-1 (complex 5) (11). In these experiments, we used EMSA to
compare the protein complexes bound to the -63/-33 element in GT17
nuclear extract with NIH 3T3 nuclear extract (Fig. 4A
).
Nuclear extract from
T31 cells was included as a second cell type
that does not express GnRH. The low mobility complex formed with GT17
nuclear extract (complex 5) was previously identified as Oct-1 by
antibody supershift analysis (11). In EMSA with NIH 3T3 nuclear
extract, a complex comigrates with the Oct-1 band from the GT17
cells, but addition of an antibody against Oct-1 does not block binding
of the complex. The Oct-1 antibody blocks binding of complex 5 in
GT17 and
T31 nuclear extract. These data suggest that either
Oct-1 does not bind to FP2 in NIH 3T3 cells or that another complex
binding with NIH 3T3 nuclear extract masks the binding of Oct-1.
Regardless, the major low mobility complex in NIH 3T3 extracts binding
to -63/-33 does not contain a significant amount of Oct-1, which may
account for the lower transcriptional activity observed in Figs. 1
and 2
. To prove that functional Oct-1 is present in NIH 3T3 cells, we show
that Oct-1 from NIH 3T3 and GT17 nuclear extracts binds appropriately
to an octamer consensus sequence (Fig. 4B
). Oct-1 binding to -63/-33
is not unique to GT17 nuclear extract since nuclear extract from
T31 cells forms the Oct-1 complex (Fig. 4A
). Additionally, two
complexes with a high mobility (complexes 1 and 2) are present in EMSA
with GT17 nuclear extract but not with NIH 3T3. In
T31 nuclear
extract, complex 1, but not complex 2, is present by EMSA. These
differences in protein complexes binding to FP2 could be responsible
for the cell type-specific interactions between the GnRH enhancer and
promoter.
To determine whether complex 1 and 2 binding to -63/-33 are specific
across various cell types, a panel of nuclear extracts was used in EMSA
with -63/-33 as a probe (Fig. 5
). The
nuclear extracts were from the following cell lines: GT17, AtT-20
(mouse pituitary corticotrope), NLT (mouse GnRH-expressing tumor from
the nasal region outside the CNS), NIH 3T3, Y1 (mouse adrenal),
T11 (mouse pituitary),
T31 (mouse pituitary gonadotrope), CV1
(monkey fibroblast), HeLa (human cervical fibroblast), and JEG-3 (human
choriocarcinoma). From the panel of nuclear extracts, it appears that
complex 2 is not present in any of the other cell types tested. In
JEG-3 cells, a complex exists that migrates slightly faster than
complex 2 from GT17 cells. It is possible that the protein from JEG-3
cells is a human homolog of the complex 2 protein in mice, but it is
more likely that this complex from JEG-3 cells is a different protein
from complex 2. Complex 1 is present in GT17 nuclear extract and
appears to comigrate with complexes seen in NLT,
T31, and
T11
nuclear extracts. Thus, complex 1 is partially cell specific and
complex 2 is unique to GT17 cells, in the tested cell types.

View larger version (95K):
[in this window]
[in a new window]
|
Figure 5. Complex 1 and Complex 2 from GT17 Nuclear Extract
Are Relatively Cell-Specific Complexes
An EMSA was conducted using the -63/-33 probe and nuclear extracts
from the different cell types, indicated above each
lane. The specific complexes labeled at left and
right were previously identified by their ability to be
competed by 100-fold excess of unlabeled oligonucleotide. Arrow
at bottom right indicates migration of free probe.
|
|
Q50 Homeodomain Transcription Factor Binding Sites Found within
Footprint 2
To identify the protein(s) contained in complex 2, we examined the
nucleotide sequence for known protein-binding elements. The -63 to
-33 region contains a CAATTA region (Fig. 6A
, middle site) that is
homologous to a C/EBP and a homeodomain-binding site. Previously, we
found that C/EBPß, although present in GT17 cells, does not bind to
this site, termed the middle site by Eraly et al. (11).
Homeodomain transcription factors recognize an ATTA DNA core motif.
Those homeodomains with a glutamine at position 50 (Q50) bind a CAATTA
or CCATTA motif while a lysine at position 50 (K50) recognizes a GGATTA
motif (18). By sequence comparison, it appears that both the middle and
downstream sites contain Q50 homeodomain binding elements (Fig. 6A
). Few of the specific Q50 homeodomain
binding sites have been determined; the best characterized include
engrailed (en), antennapedia (antp), and fushi tarazu (ftz) (19, 20, 21).
Ftz is a member of the antp family of homeodomain proteins while en is
a member of a separate family (22). En and ftz are Q50 homeodomain
transcription factors that bind a core site of CAATTA, an 8 out of 10
match to the middle site in FP2 (Fig. 6A
) (20, 21). The downstream site
of the -63/-33 promoter element is also homologous to a Q50
homeodomain binding site that can be bound by ftz or antp, based on the
core CAATTA motif (19). Thus, it is possible that members of the Q50
homeodomain protein family bind to one or both of these regions within
the -63/-33 sequence.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 6. Potential Q50 Homeodomain Protein Binding
Sites in Footprint 2
A, The GnRH promoter -63/-33 region contains two possible Q50
homeodomain binding sites. The -63/-33 oligonucleotide is shown with
boxes encompassing two regions of homology with the
fushi tarazu/engrailed (ftz/en) consensus site (middle site and
downstream site). Bold sequences correspond to the core
Q50 homeodomain binding site, and underlining identifies
regions of homology to a Q50 binding site. Alignment of the Q50
consensus binding site probe (Q50) is with the middle binding site
within FP2 of the GnRH promoter (middle site). The Q50 oligonucleotide
region within the box indicates the ftz/en consensus binding
site and encompasses the middle site in the -63/-33 element.
Vertical lines identify the bases that are conserved
between the Q50 consensus site and -63/-33. B, EMSAs were conducted
with GT17 nuclear extract and the indicated probes. The specific
complexes labeled at left and right were
previously identified by their ability to be competed by 100-fold
excess of unlabeled oligonucleotide (not shown). Arrow at bottom
right indicates migration of free probe. C, -63/-33
oligonucleotide sequence is shown with the likely complex binding
sites. Bars above and below the
sequence show the region likely bound by each complex listed.
|
|
Thus, it is important to determine whether the cell-specific complexes
1 or 2 are bound to the ATTA motifs. Previously, we conducted EMSA
analysis of mutations within the -63/-33 probe to determine the
regions binding each of the five protein complexes (11). In Table 1
, we show the mutant oligonucleotide
probe sequences below the wild-type -63/-33 oligonucleotide probe
sequence. The mutant probes lack the binding of protein complexes to
either the middle site (m2c block mutation) or to the downstream site
(m2e block mutation and m2oct double point mutation) (11). Here we list
the previous results in table form with the addition of a second block
mutation in the middle site, m2d (data not shown), and four mutated
probes corresponding to mutations in the Q50 consensus sites, m2Q1,
m2Q2, m2Q3, and m2Q4 (EMSA shown in Fig. 6B
). Complex 5 (Oct-1) and
complex 1 are greatly reduced by the m2e and m2oct mutation,
corroborating the binding of the corresponding proteins in the
downstream site of FP2 (diagram in Fig. 6C
). The new m2d mutation, as
well as the previously documented m2c mutation, eliminates complex 4
binding, suggesting that complex 4 binds to the middle FP2 binding
site. Complex 3 is eliminated by all of the block mutations including
m2d, confirming that dramatic changes in the -63/-33 oligonucleotide
disrupt complex 3. We previously indicated that m2c does not disrupt
complex 2 formation (11), but a more detailed analysis shows a
reduction in complex 2 formation on the m2c block mutation
oligonucleotide probe (see also Fig. 7A
).

View larger version (62K):
[in this window]
[in a new window]
|
Figure 7. The -63/-33 Region Binds a GT17 Cell-Specific
Protein Related to the Q50 Homeodomain Family
A, The GT17 specific complex bound to the Q50 consensus site
comigrates with complex 2 from GT17 nuclear extract. EMSAs were
conducted as described in Materials and Methods with
-63/-33, m2c, and Q50 probes, as indicated. The five specific
complexes bound in GT17 nuclear extract to -63/-33 are indicated at
the left. The Q50-specific band is indicated by the
arrow at left and is absent in the lanes with NIH 3T3
extract (A, right). The arrow at bottom
right indicates migration of free probe. Nuclear extracts from
GT17 cells (left) and NIH 3T3 cells
(right) were used in the EMSA. B, Complex 2 is competed
by the Q50 probe. EMSA was conducted using GT17 nuclear extract.
Competitions with 100-fold molar excess of the indicated
oligonucleotide were conducted; none (no competitor added), self (same
oligonucleotide as the indicated probe), m2c (-63/-33 with m2c
mutation), Q50 (oligonucleotide with ftz/en consensus binding site) and
Q50mut (Q50 oligonucleotide with mutation in homeodomain consensus
site).
|
|
Since the m2c mutation does not completely eliminate complex 2
formation, it is possible that complex 2 binds to a site at the
downstream end of -63/-33. An ATTA motif is present in both the
middle and downstream sites. To investigate the location of binding of
complex 2, targeted mutations were created in the -63/-33
oligonucleotide probe (Table 1
for compiled data and mutation
sequences). Mutation of the middle ATTA site to GGGG (m2Q1) results in
decreases in complexes 1, 2, 3, and 5 while complex 4 is completely
eliminated (Fig. 6B
). A smaller mutation in the middle site, changing
the first and fourth As to Gs (m2Q2), results in a decrease in
complex 2 binding and elimination of complex 4. The same mutation in
the downstream ATTA site (m2Q3) decreases binding of complexes 1 and 2
and eliminates binding of complex 5 (Oct-1), as expected (see above).
Since complex 4 is retained by the probe containing the downstream
mutation, it is clear that this complex requires an intact middle ATTA
site although it is not a cell-specific complex (see Fig. 5
). Complex 2
appears to bind to the CAATTA motif in the middle site (-55 to -50)
and an ATTA motif (-41 to -38) present in the downstream site.
Conversely, complex 2 may also be maintained by protein-protein
interactions even when its DNA recognition sequence has been disrupted.
Complex 1 is relatively cell specific (see Fig. 5
) and binds the
identical site as Oct-1, as is shown by its retention on the probe with
the point mutations of the middle site and its reduction by mutations
in the downstream site. Finally, an oligonucleotide probe containing
the point mutations in both middle and downstream sites (m2Q4) reduces
binding of complex 1 and eliminates binding of the remaining complexes
(Fig. 6B
). A diagram summarizing the proteins binding to -63/-33 is
shown in Fig. 6C
.
-63/-33 Binds a Complex That Comigrates with a Complex Binding to
a Q50 Homeodomain Consensus Site
To determine whether proteins expressed in GT17 cells can bind a
consensus Q50 binding site (represented by the binding site for en and
ftz, termed Q50), EMSA was conducted with -63/-33, m2c, and Q50 as
probes (Fig. 7A
). In GT17 nuclear extract, the Q50 probe is bound by
a protein complex that comigrates with complex 2 on the probe
-63/-33. This complex is not present in NIH 3T3 cell nuclear extract
(Fig. 7A
, arrow) or other cell types (see Fig. 5
). In EMSA
with nuclear extracts from hypothalamus and forebrain, but not
cerebellum, a complex is observed to comigrate with complex 2 using the
Q50 probe (data not shown). Furthermore, the Q50 oligonucleotide
competes for the binding of complex 2 bound to the -63/-33 probe
while a mutated Q50 oligonucleotide (Q50mut) does not compete for the
complex (Fig. 7B
). Additionally, -63/-33 competes for binding of the
specific complex bound to Q50 (arrow) while the m2c
oligonucleotide (disruption of the middle site) does not compete (Fig. 7B
). The two slower mobility complexes, which are abundant in both
GT17 and NIH 3T3 nuclear extract, are not competed for by the
-63/-33 oligonucleotide. These data suggest that a Q50 homeodomain
transcription member binds to -63/-33 specifically in GT17 nuclear
extract, perhaps modulating the cell-specific interactions between the
GnRH enhancer and promoter.
 |
DISCUSSION
|
---|
Specification of the expression of individual genes during the
complex processes of development and cellular differentiation is one of
the most challenging problems in the field. This central question
becomes all the more compelling when the tissue involved is the brain
and the target is a unique, well defined set of neurons. Little is
known about the neuronal regulatory elements and transcription factors
that restrict the expression of individual genes to exclusive
populations of neurons. The study of expression of the GnRH gene in the
GT17 cell line provides an opportunity to elucidate the molecular
mechanisms for neuron-specific gene expression.
In the simplest cases, cell type-specific gene expression can be traced
to the presence of transcription factors unique to the individual cell
types (23, 24, 25). As more is known about tissue-specific control regions,
it has been discovered that they often comprise complexes of
interacting elements and regulatory proteins with or without uniquely
tissue-specific factors (26, 27, 28). These more complex control regions
may have evolved to integrate diverse spatial and temporal information
in determining cell fate. The GnRH gene thus far falls into the latter
class in that the proteins identified to date are expressed in many
cell types.
The GnRH regulatory region comprises an enhancer and a proximal
promoter, which combined, can confer uniquely targeted expression in
transgenic animals, but the enhancer on a heterologous (RSV) promoter
is inadequate (M. A. Lawson and P. L. Mellon, unpublished
results). Thus, the enhancer must act coordinately with the elements in
the promoter. This high degree of interdependence between the
regulatory elements may be a quality adapted for specifying expression
to a very rare cell type, since activation requires the simultaneous
presence of multiple specific proteins, some of which bind to both the
enhancer and the promoter (11, 16).
The synergistic activation of transcription by the combination of the
GnRH enhancer and promoter regulatory regions is specific to GT17
cells and GnRH neurons. Thus, the GT17 cells express the proteins
necessary to facilitate the interaction between the enhancer and
promoter, whereas other cell lines, such as NIH 3T3 cells, do not.
Using transient transfections, we previously found that the GnRH
enhancer can confer cell-type specificity without the GnRH proximal
promoter (5). In this study, we have demonstrated that the promoter can
also confer a degree of cell type specificity in the absence of the
GnRH enhancer. FP2 strongly contributes to cell type specificity, since
deletion of FP2, when the GnRH promoter is coupled with the RSV
enhancer, abolishes preferential reporter gene expression in GT17
cells (Fig. 2B
). The specificity of FP2 action is further demonstrated
by fusion to the GnRH enhancer or the RSV enhancer, upstream of the RSV
promoter. In these instances, FP2 increased the activity ratio by only
2-fold in NIH 3T3 cells but by 15-fold in GT17 cells (Fig. 3
, A and
B). Finally, we have identified a subregion of FP2, -63/-33, that
specifically interacts with the GnRH enhancer in GT17 cells.
The footprint 2 region of the GnRH gene proximal promoter is complex
(reviewed in Ref. 16). It was shown previously that deletion of the FP2
element results in a 20-fold loss of transcriptional activation, the
most dramatic loss in activation of any of the promoter deletions (6).
Although data from DNase I footprint analysis of block mutations in the
promoter suggests the binding of three protein complexes, EMSA reveals
five individual complexes within the middle and downstream site (11).
This region also confers responsiveness to both phorbol esters and
glucocorticoids. Previous data also show the induction of a slower
mobility complex by the phorbol ester TPA, a protein kinase C activator
(6). Furthermore, the glucocorticoid receptor binds to the 5'-region of
FP2 in the equivalent area in the mouse GnRH promoter (29). Thus, the
GnRH proximal promoter element, FP2, confers neuronal specificity to
GnRH gene expression, as well as responsiveness to hormones and second
messengers.
Although FP2 is necessary for conferring several responses to GnRH gene
expression, little is known about the proteins that bind to this
region. Previously, we had identified Oct-1 binding to the 3'-portion
of FP2 (11). Oct-1 may play a role in cell-specific activation of GnRH
expression through unique interactions with other ubiquitous
transcription factors, through interactions with a GnRH neuron-specific
activator, or through interactions coupling the GnRH enhancer to the
GnRH promoter. The data presented here show that FP2 of the GnRH
promoter can greatly augment transcriptional activation by the GnRH
enhancer, thereby demonstrating cross-talk between FP2 and the GnRH
enhancer. Oct-1 may be one of the regulators required for this
interaction, particularly in consideration of its critical role in
transcriptional activation through binding sites in the enhancer
(7).
To identify potential cell-specific proteins in GT17 cells, we
compared EMSA between GT17 and various other cell types. Three
differences exist between GT17 and NIH 3T3 nuclear factors binding to
the -63/-33 region of the promoter that could play a role in
cell-specific expression of GnRH. First, Oct-1 containing complexes are
not detected by EMSA that include the -63/-33 region of the GnRH
promoter and nuclear extract from NIH 3T3 cells, in contrast to
assays containing nuclear extract from GT17 cells. Rather, in assays
utilizing nuclear proteins derived from NIH 3T3 cells, a strong,
comigrating, but as yet unidentified, complex forms. It is possible
that this complex masks Oct-1 binding or that the formation of the
strong, low-mobility complex occludes Oct-1 binding by occupying
nucleotide sequences necessary for Oct-1 interaction with the -63/-33
site. As mentioned earlier, binding sites for Oct-1 are also present in
the GnRH enhancer, and it is possible that the synergy between the two
elements could be due to Oct-1 or an Oct-1 binding partner. Although
formation of Oct-1 complexes on the -63/-33 site with NIH 3T3 nuclear
extract is not observed, Oct-1 complexes from pituitary-derived
T31 nuclear extracts are detected. Furthermore, expression through
the GnRH enhancer and promoter in
T31 cells is lower than in NIH
3T3 cells (data not shown), indicating that the ability of Oct-1 to
bind -63/-33 alone is not sufficient to confer cell-specific
expression. This observation suggests that other factors dependent on
Oct-1 interaction may be important for cell-specific activation of the
GnRH promoter rather than Oct-1 itself.
A second candidate for cell-specific activation is complex 1. This
complex is not present in NIH 3T3 nuclear extract whereas it appears to
be present in
T31 nuclear extract by EMSA comigration experiments.
Again, since
T31 cells express lower levels of reporter gene
driven by the GnRH enhancer and promoter than NIH 3T3 cells, the
presence of complex 1 is not sufficient to facilitate cell-specific
interactions between the GnRH promoter and enhancer. A third candidate,
that which forms complex 2, is relatively unique to GT17 cells by
EMSA and may account for the differences seen in transcriptional
regulation between the cell types. As described earlier, the GnRH
enhancer fused to the 4x-63/-33 region results in a higher reporter
expression in GT17 cells compared with NIH 3T3 cells. To further
support this idea, the m2c mutation in the -63/-33 EMSA probe
decreased binding of complex 2 (Fig. 7A
). When the m2c mutation is
present in the context of the whole promoter and enhancer, reporter
gene expression is only 25% of wild type, the most significant
decrease of all of the FP2 mutations examined to date (11). Thus, it is
likely that complex 2 plays a role in maintaining cell type specificity
and in transcriptional activation of GnRH expression.
Complex 2 is our best candidate for a cell-specific protein binding to
FP2. Expression of complex 2 appears to be restricted to GT17 cells
and to bind a potential Q50 homeodomain transcription factor site,
CAATTA. This site is also present in repeating elements in the
3'-region of the GnRH enhancer. EMSA experiments have confirmed that
complexes that form on these elements in GT17 nuclear extracts
comigrate with complex 2 (data not shown, C. G. Kelley and P.
L. Mellon, personal communication). This similarity suggests that
complex 2 may also bind to the GnRH enhancer and could subsequently
foster interactions between the two regulatory regions.
All homeodomain transcription factors bind to the core motif ATTA,
which makes it difficult to identify the protein binding by simple
binding site homology. Additionally, only a few specific homeodomain
DNA-binding sites have been well characterized. To date, antennapedia,
engrailed, and fushi tarazu are the only homeodomain proteins known to
bind to a CAATTA site (21), and the crystal structure of engrailed
bound to TAATTA has been shown (30). In EMSA experiments we have
identified a complex that binds specifically with GT17 nuclear
extract to both the -63/-33 probe and the CAATTA site. We have not
yet identified the protein(s) in this complex since supershift
antibodies are not available for Q50 homeodomain candidates,
antennapedia, engrailed, or fushi tarazu. We have found engrailed 2 RNA
and protein in GT17 neurons (data not shown) but engrailed 2 has not
been shown to be expressed in regions known to contain GnRH neurons
(31, 32). Furthermore, Hox proteins, mammalian homologs of
antennapedia, are not expressed in the forebrain, and fushi tarazu has
no known mammalian homolog. Thus, complex 2 binds to a core homeodomain
site in the GnRH promoter and may be a novel or previously identified
member of the Q50 homeodomain family. Future experiments will focus on
identification of this cell-specific regulator of GnRH gene
expression.
In conclusion, we have identified a 31-bp region (-63 to -33) of the
rat GnRH promoter that interacts with the GnRH enhancer to increase
cell-specific transcription. This region binds Oct-1, which may
interact with other ubiquitous or specific transcription factors to
control the cell-specific expression. Binding of Oct-1 to the GnRH
enhancer and to FP2 of the promoter also may be crucial for the
interaction between these two DNA regulatory elements. The data
presented here substantiate the assertion that the interactions
occurring between the GnRH enhancer and GnRH promoter are necessary for
cell-specific reporter gene expression. We have identified
cell-specific complexes binding the GnRH promoter that may play a
role in interactions between the GnRH enhancer and promoter to control
cell-specific expression of GnRH. Here, we suggest that a Q50
homeodomain transcription factor binds to a region of the GnRH promoter
that is crucial for neuron-specific interactions with the GnRH
enhancer. This protein may interact with other proteins, such as Oct-1
bound to the GnRH promoter and/or enhancer to confer cell-specific
expression. Further investigations of cognate binding proteins and
their protein-protein interactions will help to clarify the role of the
FP2 element in GnRH transcription, elucidating the molecular mechanisms
underlying the interactions between the enhancer and promoter of the
GnRH gene.
 |
MATERIALS AND METHODS
|
---|
Plasmids and Cloning
The rGnRHe/rGnRHp-luc plasmid contains the rat GnRH enhancer
(-1571 to -1863; in reverse orientation) and rat GnRH promoter (-173
to +112) in the pGL3 basic vector, controlling luciferase gene
expression. Deletions of the rat GnRH promoter were created as
previously described (11). Briefly, deletion of FP6 and FP7 retains
-126 to +112; deletion of FP2 retains -173 to -70 and -28 to +112;
deletion of FP3, 4, 5, 6, and 7 retains -82 to +112; and deletion of
FP2, 3, 4, 5, 6, and 7 retains -28 to +112. In addition, the plasmid
with the internal deletion of FP3, 4, and 5 retains the -173 to -128
and -74 to +112 region. These regions were subcloned from the CAT
vectors into the pGL3 vector (Promega Corp., Madison, WI),
containing the rat GnRH enhancer. The RSVe/rGnRHp-luc plasmid was
created by placing the enhancer region of the RSV 5'-LTR and the rat
GnRH promoter (-173 to +112) upstream of the luciferase gene in pGL3
basic. To place the RSV enhancer adjacent to the promoter deletions,
the promoter deletions were transferred from the pGL3 vector containing
the rGnRH enhancer to the pGL3 vector containing the RSV enhancer. The
rGnRHe/RSVp-luc plasmid contains the rat GnRH enhancer (-1571 to
-1863) and the promoter region from the RSV 5'-LTR in the pGL3 basic
vector. RSVe/RSVp-luc contains the enhancer and promoter regions of the
RSV 5'-LTR in the pGL3 basic vector. RSVe/RSVp-gal was created by
removing the luciferase gene from the RSVe/RSVp-luc plasmid and
replacing it with ß-galactosidase from pSV-ß-galactosidase
(Promega Corp.).
To create rGnRHe/FP2/RSVp-luc, the FP2 region (-82 to -21) was
inserted between the rat GnRH enhancer and RSV promoter in the
rGnRHe/RSVp-luc vector. RSVe/FP2/RSVp-luc contains RSVe/RSVp-luc with
FP2 (-82 to -21) inserted in the polylinker between the RSV enhancer
and RSV promoter. The -63/-33 region was multimerized by using a
synthesized oligonucleotide with the following sequence:
5'-CTAGAAGGTGTTCCAATTACATTCCTCATTAAATGG3-' and
5'-CTAGTCCATTTAATGAGGAATGTAATTGGAACACCTT-3'.
The oligonucleotide was annealed and inserted into
pBSK+. To create the four multimer site, multiple
rounds of digestion and ligation were conducted. The 4x -63/-33
multimer was then inserted between the enhancer and promoter of
rGnRHe/RSVp-luc and RSVe/RSVp-luc to create rGnRHe/4x63/RSVp-luc and
RSVe/4x63/RSVp-luc, respectively.
Cell Culture and Transfections
GT17 and NIH 3T3 cells were cultured in DMEM containing 10%
FCS (Omega Scientific, Tarzana, CA), Penn/Strep, glucose, and sodium
bicarbonate. These cells were incubated in 5%
CO2 at 37 C. For transient transfections, GT17
cells were split 1:3 and NIH 3T3 were split 1:25 from 100% confluent
plates in 6-cm plates. Cells were incubated overnight and were
transfected with calcium phosphate (33). Briefly, 7.2 µg of reporter
DNA and 2.2 µg of internal control DNA were added to a 15-ml conical
tube; 2x HBS (0.5 ml) was added to the DNA and briefly vortexed, and
0.25 M calcium chloride (0.5) was added drop wise into the
tube while vortexing at low speed. The precipitate was incubated 5 min
at room temperature before addition of 0.5 ml to one 6-cm plate of
GT17 cells and one 6-cm plate of NIH 3T3 cells. Sixteen hours later
the cells were washed two times with PBS, and DMEM 10% FCS was
replaced. Cells were incubated 24 h longer and harvested.
Harvesting cells entailed washing the cells three times with PBS and
adding harvesting buffer (0.5 ml; 0.15 M NaCl, 1
mM EDTA, and 40 mM Tris-HCl, pH 7.4). Cells
were scraped from the plate and placed in 1.5-ml tubes and spun for 30
sec at 14,000 rpm. Buffer was removed, lysis buffer (50 µl; 100
mM potassium phosphate, pH 7.8, 0.2% Triton X-100) was
added, and cells were resuspended by vortexing. Cells were spun for 5
min, and supernatant was placed into a new tube and assayed for
luciferase and ß-galactosidase activity (Galacto-Light Plus Kit,
Tropix, Inc., Bedford, MA). For the luciferase assay, cell lysate (10
µl) was assayed in a 96-well plate, which was read in a luminometer
(Microlumat Plus; Microplate Luminometer LB96V; EG&G Berthold,
Gaithersburg, MD) using luciferin assay buffer (100 µl; 100
mM Tris, pH 7.8, 15 mM
MgSO4, 10 mM ATP and 65
µM luciferin). For the ß-galactosidase assay, cell
lysate (10 µl) and 0.25 M Tris, pH 7.8 (10 µ l),
were combined and incubated at 48 C for 50 min. This was transferred to
a 96-well plate, and diluted Galacton-Plus Substrate (70 µl; 1:100 in
Galacto-Light Reaction Buffer Diluent) was added to each well. The
plate was incubated for 15 min and assayed using the luminometer. Light
Emission Accelerator (100 µl) was injected into each well and read
for 10 sec after a 2-sec delay. The luciferase and
ß-galactosidase values for a nontransfected plate of cells were
subtracted from each transfected plate value. Then luciferase values
were divided by the ß-galactosidase values to control for
transfection efficiency.
Normalizing Transfection Data and Statistics
To control for differences in expression between the different
cell types, each experiment was normalized. The RSV enhancer fused to
the RSV promoter driving luciferase (RSVe/RSVp-luc) was transfected in
duplicate in each experiment. The internal control, RSVe/RSVp fused to
ß-galactosidase (RSVe/RSVp-gal), was used as an internal control for
each transfected plate of cells. The RSVe/RSVp-luc luciferase values
were divided by the RSVe/RSVp-gal ß-galactosidase values and
averaged. The average was set to 1, and the values for the other plates
were normalized to this value in the individual cell types. Thus, the
values from the individual cell types can be directly compared. The
mean of at least three experiments is depicted. The error bars
represent SEM. In Fig. 1
, a single-factor ANOVA and
Dunnetts Least Significant Difference (LSD) Test were used to
determine significant difference. In Figs. 2
and 3
, significance was
measured by paired t test analysis, P
0.05 as indicated by asterisks.
Oligonucleotides
The -63/-33 oligonucleotide corresponds to the sequences
-63 to -38 and -59 to -33. The m2c, m2d, and m2e oligonucleotides
are identical to the -63/-33 oligonucleotide except for the
substitution of 5'-GCGGCCGC-3' at -58 to -51, -53 to -46, and -45
to -38, respectively. The m2oct oligonucleotide is identical to
-63/-33 with a substitution of a G for the T at positions -47 and
-40. The m2Q oligonucleotides are identical to -63/-33 with the
substitution of Gs for the ATTA from -50 to -53 (m2Q1), a G for the
A at positions -50 and -53 (m2Q2), a G for the A at positions -38
and -41 (m2Q3), and a G for the A at positions -38, -41, -50, and
-53 (m2Q4). The fushi tarazu/engrailed (ftz/en) consensus binding
oligonucleotide (Q50) corresponds to the sequences
CTAGGAAATGTCAATTAAATATCAAG (top strand), and GATCGCTTGATATTTAATTGACATTC
(bottom strand). The ftz/en consensus mutant (Q50mut) oligonucleotide
corresponds to the sequences CTAGGAAATGTCAGGGAATATCAAG (top strand) and
GATCGCTTGATATTCCCCTGACATTTC (bottom strand). Oligonucleotides were
synthesized by Operon Technologies (Alameda, CA) and were
annealed in 50 mM NaCl by heating to 95 C for 5 min and
slowly cooling to room temperature.
EMSA
Nuclear extracts were prepared according to the method
described by Schreiber et al. (34). Annealed wild-type and
mutant oligonucleotides (1 pmol) containing sequences of the GnRH
promoter and consensus sequences were filled in with
[32P]dATP (3000 Ci/mmol Dupont NEN Life Science Products, Boston, MA) and Klenow using standard
procedures (35). Probes were phenol/chloroform extracted and passed
over G-50 micro columns (Amersham Pharmacia Biotech,
Piscataway NJ). Probes were counted in a scintillation counter and
diluted in 50 mM NaCl. The competitor
oligonucleotide was end-filled with Klenow. Binding reactions were
carried out in 10 mM HEPES-KOH, pH 7.8, 50
mM KCl, 1 mM EDTA, 5
mM spermidine, 5 mM DTT,
0.2 mg/ml BSA, 0.5 mM
phenylmethylsulfonylfluoride, 12.525 µg/ml
polydeoxyinosinic-deoxycytidylic acid, 10% (vol/vol) glycerol, and 20
mg/ml Ficoll. One femtomole of each probe was incubated with 2 µg of
GT17 crude nuclear extract in 20 µl reactions. Reactions were
incubated at room temperature for 5 min, loaded, with current on, into
a 5% polyacrylamide gel [30:1 acrylamide/bisacrylamide, 0.25 x
TBE (130 mM Tris, 45 mM
boric acid, 2.5 mM EDTA), 5% glycerol], and
electrophoresed for 2 to 3 h at 175 V. Gels were prerun for 30 min
in 0.25 x TBE. After electrophoresis, gels were dried and
subjected to autoradiography. Competition reactions were performed by
preincubating the reactions with the specified amount of excess
unlabeled oligonucleotide for 20 min before the addition of probe.
 |
ACKNOWLEDGMENTS
|
---|
The authors would like to thank Melody Clark, Naama Rave-Harel,
Bridgette Kirkpatrick, Patrick Chappell, and Sandra Holley for
discussions and reading of the manuscript; Satish Eraly, Karen Huang,
and Kelley Chuang for creation of reporter plasmids; and Scott
Anderson, Sally Hall, Brian Powl, Teri Williams, Melinda Merrill, Kevin
Rufner, Kevin Urayama, and Debbie Kwok for technical support.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Pamela L. Mellon, Ph.D., Department of Reproductive Medicine 0674, 2057 Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0674.
This work was supported by NIH Grant R01 DK-44838 (to P.L.M.). S.B.N.
was partially supported by NIH Training Grant T32 AG00216. C.G.K. was
supported by a predoctoral fellowship from the Howard Hughes Medical
Institute.
Received for publication October 28, 1999.
Revision received May 24, 2000.
Accepted for publication May 30, 2000.
 |
REFERENCES
|
---|
-
Silverman A 1988 The gonadotropin-releasing hormone
(GnRH) neuronal systems: Immunocytochemistry. In: Knobil E, Neill JD
(eds) The Physiology of Reproduction. Raven Press, New York, vol 1:12831304
-
Fink G 1988 Gonadotropin secretion and its control. In:
Knobil E, Neill J (eds) The Physiology of Reproduction. Raven Press,
New York, vol 1:13491378
-
Schwanzel-Fukuda M, Pfaff DW 1989 Origin of luteinizing
hormone-releasing hormone neurons. Nature 338:161164[CrossRef][Medline]
-
Mellon PL, Windle JJ, Goldsmith P, Pedula C, Roberts J,
Weiner RI 1990 Immortalization of hypothalamic GnRH neurons by
genetically targeted tumorigenesis. Neuron 5:110[Medline]
-
Whyte DB, Lawson MA, Belsham DD, Eraly SA, Bond CT, Adelman
JP, Mellon PL 1995 A neuron-specific enhancer targets expression of the
gonadotropin-releasing hormone gene to hypothalamic neurosecretory
neurons. Mol Endocrinol 9:467477[Abstract]
-
Eraly SA, Mellon PL 1995 Regulation of GnRH transcription by
protein kinase C is mediated by evolutionarily conserved,
promoter-proximal elements. Mol Endocrinol 9:848859[Abstract]
-
Clark ME, Mellon PL 1995 The POU homeodomain transcription
factor Oct-1 is essential for activity of the gonadotropin-releasing
hormone neuron-specific enhancer. Mol Cell Biol 15:61696177[Abstract]
-
Lawson MA, Whyte DB, Mellon PL 1996 GATA factors are
essential for activity of the neuron-specific enhancer of the
gonadotropin-releasing hormone gene. Mol Cell Biol 16:35963605[Abstract]
-
Lawson MA, Buhain AR, Jovenal JC, Mellon PL 1998 Multiple
factors interacting at the GATA sites of the gonadotropin-releasing
hormone neuron-specific enhancer regulate gene expression. Mol
Endocrinol 12:364377[Abstract/Free Full Text]
-
Wierman ME, Xiong X, Kepa JK, Spaulding AJ, Jacobsen BM, Fang
Z, Nilaver G, Ojeda SR 1997 Repression of gonadotropin-releasing
hormone promoter activity by the POU homeodomain transcription factor
SCIP/Oct-6/Tst-1: a regulatory mechanism of phenotype expression? Mol
Cell Biol 17:16521665[Abstract]
-
Kelley CG, Lavorgna G, Clark ME, Boncinelli E, Mellon PL 2000 The Otx2 homeoprotein regulates expression from the
gonadotropin-releasing hormone proximal promoter. Mol Endocrinol 14:12461256[Abstract/Free Full Text]
-
Eraly SA, Nelson SB, Huang KM, Mellon PL 1998 Oct-1 binds
promoter elements required for transcription of the
gonadotropin-releasing hormone gene. Mol Endocrinol 12:469481[Abstract/Free Full Text]
-
Lawson MA, Mellon PL 1998 Expression of GATA-4 in migrating
GnRH neurons of the developing mouse. Mol Cell Endocrinol 140:157161[CrossRef][Medline]
-
Matsuo I, Kuratani S, Kimura C, Takeda N, Aizawa S 1995 Mouse
OTX2 functions in the formation and patterning of rostral head. Genes
Dev 9:26462658[Abstract]
-
Acampora D, Mazan S, Lallemand Y, Avantaggiato V, Maury M,
Simeone A, Brulet P 1995 Forebrain and midbrain regions are deleted in
OTX2-/- mutants due to a defective anterior neuroectoderm specification
during gastrulation. Development 121:32793290[Abstract/Free Full Text]
-
Ang S-L, Jin O, Rhinn M, Daigle N, Stevenson L, Rossant J 1996 A targeted mouse OTX2 mutation leads to severe defects in gastrulation
and formation of axial mesoderm and to deletion of rostral brain.
Development 122:243252[Abstract/Free Full Text]
-
Nelson SB, Eraly SA, Mellon PL 1998 The GnRH promoter: Target
of transcription factors, hormones, and signaling pathways. Mol Cell
Endocrinol 140:151155[CrossRef][Medline]
-
Lei Z, Rao CV 1997 Cis-acting elements and trans-acting
proteins in the transcriptional inhibition of gonadotropin-releasing
hormone gene by human chorionic gonadotropin in immortalized
hypothalamic GT17 neurons. J Biol Chem 272:1436514371[Abstract/Free Full Text]
-
Hanes SD, Brent R 1991 A genetic model for interaction of the
homeodomain recognition helix with DNA. Science 251:426430[Medline]
-
Müller M, Affolter M, Leupin W, Otting G, Wüthrich
K, Gehring WJ 1988 Isolation and sequence-specific DNA binding of the
Antennapedia homeodomain. EMBO J 7:42994304[Abstract]
-
Florence B, Handrow R, Laughon A 1991 DNA-binding specificity
of the fushi tarazu homeodomain. Mol Cell Biol 11:36133623[Medline]
-
Desplan C, Theis J, OFarrell PH 1988 The sequence
specificity of homeodomain-DNA interaction. Cell 54:10811090[Medline]
-
Duboule D 1994 Guidebook to the Homeobox Genes. Oxford
University Press, Oxford, UK
-
Maniatis T, Goodbourn S, Fischer JA 1987 Regulation of
inducible and tissue-specific gene expression. Science 236:12371245[Medline]
-
Mitchell PJ, Tjian R 1989 Transcriptional regulation in
mammalian cells by sequence-specific DNA binding proteins. Science 245:371378[Medline]
-
Luo Y, Fujii H, Gerster T, Roeder RG 1992 A novel B
cell-derived coactivator potentiates the activation of immunoglobulin
promoters by octamer-binding transcription factors. Cell 71:231241[Medline]
-
He X, Rosenfeld MG 1991 Mechanisms of complex transcriptional
regulation: Implications for brain development. Neuron 7:183196[Medline]
-
Struhl K 1991 Mechanisms for diversity in gene expression
patterns. Neuron 7:177181[Medline]
-
Goudet G, Delhalle S, Biemar F, Martial JA, Peers B 1999 Functional and cooperative interactions between the homeodomain PDX1,
Pbx, and Prep1 factors on the somatostatin promoter. J Biol Chem 274:40674073[Abstract/Free Full Text]
-
Chandran UR, Attardi B, Friedman R, Zheng Z, Roberts JL,
DeFranco DB 1996 Glucocorticoid repression of the mouse
gonadotropin-releasing hormone gene is mediated by promoter elements
that are recognized by heteromeric complexes containing glucocorticoid
receptor. J Biol Chem 271:2041220420[Abstract/Free Full Text]
-
Kissinger CR, Liu BS, Martin-Blanco E, Kornberg TB, Pabo CO 1990 Crystal structure of an engrailed homeodomain-DNA complex at 2.8 A
resolution: a framework for understanding homeodomain-DNA interactions.
Cell 63:579590[Medline]
-
Davis CA, Holmyard DP, Millen KJ, Joyner AL 1991 Examining
pattern formation in mouse, chicken and frog embryos with an
En-specific antiserum. Development 111:287298[Abstract]
-
Davidson D, Graham E, Sime C, Hill R 1988 A gene with sequence
similarity to Drosophila engrailed is expressed during the development
of the neural tube and vertebrae in the mouse. Development 104:305316[Abstract]
-
Mellon PL, Parker V, Gluzman Y, Maniatis T 1981 Identification
of DNA sequences required for transcription of the human
1 globin gene using a new SV40 host-vector
system. Cell 27:279288[Medline]
-
Schreiber E, Matthias P, Müller M, Schaffner W 1989 Rapid detection of octamer binding proteins with mini-extracts prepared
from a small number of cells. Nucleic Acids Res 17:6419[Medline]
-
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith
JA, Struhl K 1987 Current Protocols in Molecular Biology, John Wiley &
Sons, New York